These results were in accordance with the results in our cohort that the prognosis was similar for CTD-PAH patients with the low-stability and early-remission NT-proBNP trajectories, of which the NT-proBNP levels remained at or improved to a low risk after 3 months of follow-up assessments. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.